本文選題：幽門(mén)螺桿菌　切入點(diǎn)：中性白細(xì)胞激活蛋白　出處：《鄭州大學(xué)》2005年博士論文

【摘要】：幽門(mén)螺桿菌(Helicobacter pylori,H.pylori)是一種微需氧革蘭氏陰性螺旋桿菌,在全球人口中的感染率超過(guò)50%。H.pylori感染多發(fā)生在兒童時(shí)期,如果不經(jīng)治療,H.pylori在胃中的持續(xù)慢性感染可導(dǎo)致胃炎、消化道潰瘍等疾病,并與胃癌、胃黏膜相關(guān)性淋巴樣組織(MALT)淋巴瘤發(fā)生密切相關(guān)。研制疫苗將是控制H.pylori感染及相關(guān)疾病經(jīng)濟(jì)有效的途徑。 H.pylori水抽提物中存在著一種能趨化并激活中性白細(xì)胞的可溶性蛋白,被稱作幽門(mén)螺桿菌中性白細(xì)胞激活蛋白(H.pylori neutrophil-activating protein,HP-NAP)。HP-NAP位于幽門(mén)螺桿菌細(xì)胞質(zhì)中,可通過(guò)細(xì)菌自溶而釋放,并附著在細(xì)菌外膜的表面,HP-NAP對(duì)高分子量碳水化合物具有特異親和力,處于這樣的位置HP-NAP可能介導(dǎo)幽門(mén)螺桿菌粘附于縮主胃黏膜上皮細(xì)胞表面。多數(shù)H.pylori感染者血清中存在HP-NAP特異抗體,HP-NAP被認(rèn)為是幽門(mén)螺桿菌感染的重要因子和疫苗候選抗原。 本研究利用PCR方法從H.pylori臨床分離株MEL-HP27基因組DNA中克隆HP-NAP編碼基因HP-napA,利用生物信息技術(shù)對(duì)HP-napA進(jìn)行序列分析和功能預(yù)測(cè),DNA重組技術(shù)構(gòu)建原核表達(dá)載體,并對(duì)其編碼產(chǎn)物的免疫原性、免疫反應(yīng)性進(jìn)行研究,從阻斷H.pylori黏附與定植的角度觀察HP-NAP在動(dòng)物模型中的免疫保護(hù)效果,以評(píng)價(jià)其在發(fā)展H.pylori基因工程疫苗中的作用,為免疫接種預(yù)防H.pylori感染,減少H.pylori相關(guān)疾病奠定基礎(chǔ)。 實(shí)驗(yàn)方法 1.H.pylori MEL-HP27菌株HP-napA基因的分子克隆及序列分析
[Abstract]:Helicobacter pylori H.pylori, a microaerobic gram-negative helicobacter pylori, is more prevalent in the global population than in childhood, and a persistent chronic infection of H.pylori in the stomach without treatment can lead to gastritis. Gastrointestinal ulcer and other diseases are closely related to gastric cancer and gastric mucosa-associated lymphoid tissue lymphoma. The development of vaccine will be an economical and effective way to control H.pylori infection and related diseases. There is a soluble protein in H.pylori water extract that can chemoattractant and activate neutrophil. It is called H. pylori neutrophil-activating protein HP-NAPP. HP-NAP is located in the cytoplasm of Helicobacter pylori and can be released by bacterial autolysis. The HP-NAP attached to the bacterial outer membrane has specific affinity to high molecular weight carbohydrates. In this position, HP-NAP may mediate the adhesion of Helicobacter pylori to the surface of gastric epithelial cells. The presence of HP-NAP in the sera of most H.pylori infected patients is considered to be an important factor and vaccine candidate antigen for Helicobacter pylori infection. In this study, PCR method was used to clone the HP-NAP encoding gene HP-napA from the genomic DNA of H.pylori clinical isolate MEL-HP27. Sequence analysis and functional prediction of HP-napA were used to construct the prokaryotic expression vector, and the immunogenicity of the encoding product was analyzed. The immunoreactivity was studied to observe the immune protection effect of HP-NAP in animal model from the view of blocking the adhesion and colonization of H.pylori in order to evaluate its role in the development of H.pylori gene engineering vaccine and to prevent H.pylori infection. Reduce H.pylori related diseases to lay the foundation. Experimental method. Molecular cloning and sequence Analysis of HP-napA Gene of 1.H.pylori MEL-HP27 strain
【學(xué)位授予單位】：鄭州大學(xué)
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2005
【分類(lèi)號(hào)】：R392

【參考文獻(xiàn)】

相關(guān)期刊論文 前1條

1 范學(xué)工,劉征波;幽門(mén)螺桿菌感染的免疫發(fā)病機(jī)制[J];華人消化雜志;1998年02期

，

本文編號(hào)：1698191